Business
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. Context will prese
About this update from Context Therapeutics Inc.
[{"type":"image","alt":"Context Therapeutics Inc.","displaySize":"","headline":null,"caption":"Context Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YbSmZ9VBJ1k54h3C06aWkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85","width":300,"height":140}},"lazy":false},{"type":"text","content":"PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.","length":481,"tagName":"p"},{"type":"text","content":"Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs. This is the dose level expected to lead to a minimal biological effect level in humans. The weight of evidence of these data supports the safety of the proposed clinical starting dose of 0.1 μg/kg for CT-95.","length":409,"tagName":"p"},{"type":"text","content":"Poster Presentation Details:","length":28,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin","length":109,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Abstract Number: ","length":16,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-ali...